Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Neoadjuvant therapy for patients with upper tract urothelial carcinoma

Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, outlines data on upper tract urothelial carcinoma (UTUC) neoadjuvant treatment. Data presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers (GU) Symposium 2022, strongly supports the use of perioperative chemotherapy for UTUC. However, many patients are ineligible for postoperative platinum-based chemotherapy following resection and can better tolerate the process of chemotherapy in the neoadjuvant setting. The survival outcome of advanced UTUC is poor and neoadjuvant chemotherapy could provide a new treatment approach that could benefit this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.